Skip to main content
Log in

Endothelin and Heart Failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

The availability of potent and orally active nonpeptide endothelin (ET) receptor antagonists has generated a host of information on the pathophysiological role of ET-1 in a number of preclinical models including hypertension, renal failure, heart failure and pulmonary hypertension. Convincing data are available to show that ET-1 receptor antagonists are beneficial in humans as far as reversal of deranged systemic and regional hemodynamics associated with CHF and pulmonary hypertension. As in other disease areas, the issue of whether ETA-selective or ETA/B antagonists are more suited for CHF treatment remains unresolved. ETB receptors may mediate some critical processes in the kidney such as sodium and water excretion in addition to releasing vasodilator substances such as NO and prostacyclin from endothelial cells. In heart failure and chronic renal diseases, preservation of ETB-mediated responses in the kidney and pulmonary endothelium might be beneficial. On the other hand, blockade of ETB-mediated vasoconstriction, smooth muscle cell proliferation and fibrosis by ETB antagonists might be beneficial. In clinical trials so far, the hemodynamic effects of mixed antagonists of ET receptors and ETA selective antagonists seem equivalent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Inoue A, Yanagisawa M, Kimura S, Kasuga Y, Miyuchi T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci 1989; 86:2863–2867.

    Google Scholar 

  2. Simonson M, Dunn M. Cellular signalling by peptides of the endothelin gene family. FASEB J 1990;4:2989–3000.

    Google Scholar 

  3. Resink T, Scott-Burden T, Buhler F. Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur J Biochem 1990;189:415–421.

    Google Scholar 

  4. Liu Y, Geisburhler B, Jones A. Activation of multiple mechanisms including phospholipase D by endothelin-1 in rat aorta. Am J Physiol 1992;262:C941–C946.

    Google Scholar 

  5. Lonchampt M, Pinelis S, Goulin J, Chabrier P, Braquet P. Proliferation and Na+/H+ exchange activation by endothelin in vascular smooth muscle cells. Am J Hypertension 1991;4:776–779.

    Google Scholar 

  6. Wang Y, Rose P, Webb M, Dunn M. Endothelins stimulate mitogen activated protein kinase cascade through either ETA or ETB. Am J Physiol 1994; 267:C1130–C1135.

    Google Scholar 

  7. Cazanbon S, Ramos-Morales F, Fischer S, Schweighoffer F, Strosberg A, Courand P. Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes. J Biol Chem 1994;269:24805–24809.

    Google Scholar 

  8. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;36:703–710.

    Google Scholar 

  9. Hosada K, Hammer R, Giad A, Richardson J, Baynash A. Targeted and natural (piebald-lethal) mutations of endothelin B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994;79: 1267–1276.

    Google Scholar 

  10. Puffenberger E, Hosada K, Washington S, Nakao K, deWit D. A missense mutation of the endothelin B-receptor gene in multigenic Hirschsprung's disease. Cell 1994;79:1257–1266.

    Google Scholar 

  11. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yangisawa M, Kumada M. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 1999;276:R1071–R1077.

    Google Scholar 

  12. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor–deficient rats. J Clin Invest 2000;105:925–933.

    Google Scholar 

  13. Pollock D, Portik-Dobos V, Procter C, Gariepy C. Arterial pressure response to ET-1 and S6c in rescued ETB-deficient rats. Sixth international conference on Endothelin, Montreal, Canada. 1999.

  14. Opgenorth T, Wessak J, Dixon D, Adler A, Calzadillar S, R P, Wu-Wong J. Effects of endothelin receptor antagonists on the plasma ir ET-1 level. Sixth international conference on Endothelin, Montreal, Canada. 1999.

  15. Matsumura Y, Kuro T, Kobayashi Y, Konishi F, Takaoka M, Wessale JL, Opgenorth TJ, Gariepy CE, Yanagisawa M. Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor–Deficient Rats With Deoxycorticosterone Acetate–Salt Hypertension. Circulation 102:2765–2773, 2000.

    Google Scholar 

  16. Berthiaume N, Yanagisawa M, Labonte J, D'Orléans-Juste P. Heterozygous knock-out of ETB receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 36:1002–1007, 2000.

    Google Scholar 

  17. Ihara M, Noguchi K, Sacki T, Fukuroda M, Tsuchida S. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247–255.

    Google Scholar 

  18. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N. Biochemical and pharmacological profile of a potent and selective endothelin-B receptor antagonist. Proc Natl Acad Sci 1994;91:48192–48196.

    Google Scholar 

  19. Clozel M, Breu V, Gray G, Kalina B, Loffler B. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin antagonist. J Pharmacol Exp Ther 1994;270:228–235.

    Google Scholar 

  20. Ohlstein E, Nambi P, Douglas S, Edwards R, Gellai M, Lago A. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci 1994:8052–8056.

  21. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353–355.

    Google Scholar 

  22. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. Increased production of endothelin-l in the hypertrophied rat heart due to pressure overload. FEBS Lett 1993;332:31–34.

    Google Scholar 

  23. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M. Contribution of endogenous endothelin-1 to the Endothelin and Heart Failure 339 progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Cir Research 1993;73:887–897.

    Google Scholar 

  24. McMurray J, Ray S, Abdullah I, Dargie H, Morton J. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374–1379.

    Google Scholar 

  25. Omland T, Lie R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation 1994;89:1573–1579.

    Google Scholar 

  26. Wei C, Lerman A, Rodeheffer R, McGregor C, Grandt R, Wright S. Endothelin in human congestive heart failure. Circulation 1994;89:1580–1586.

    Google Scholar 

  27. Pacher R, Berger-Klein J, Globits S, Tenfelsbauer H, Schuller M, Krauter A. Plamsa big endothelin-l concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993;71:1293–1299.

    Google Scholar 

  28. Pieske B, Beyermann B, Breu V, Loffler B, Schlotthauer K, Maier L, Schmidt-Schweda S, Just H, Hasenfuss G. Functional effects of endothelin and regulation of endothelin responses in isolated nonfailing myocardium. Circulation 1999;99:1802–1809.

    Google Scholar 

  29. Beyer M, Nerz S, Kazmaier S, Hoffmeister H. Effect of endothelin-1 and its combination with adenosine on myocardial contractility and myocardial energy metabolism in vivo. J Mol Cell Cardiol 1995;27:l989–1997.

    Google Scholar 

  30. Ponicke K, Vogdsang M, Hienroth M, Becker K, Zolk O, Bohm M, Zerkowski H, Brodde O. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998;97:744–75l.

    Google Scholar 

  31. Mulder P, Richard V, Derumeaux G, Hogie M, Henry J, Lallemand F, Compagnon P, Mace B, Comey E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure. Effect of a long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation 1997;96:1976–1982.

    Google Scholar 

  32. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, Kinoshita M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 1997;30:1385–1392.

    Google Scholar 

  33. Barton M, Better D, d'Uscio L, Brandes R, Lattermann T, Lyuzkanov G, Shaw S, Lucher T. Initiation of endothelin ETA antagonist treatment six months after myocardial infarction improves heart failure indices in rats with chronic congestive heart failure. Sixth International Conference on Endothelin, Montreal, Canada. 1999.

  34. Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, Yabana H, Goto K, Sugishita Y, Murata S. Role of endothelin in determination of heart failure due to cardiomopathy in hamsters. Increase in endothelin-1 production in the heart and beneficial effect of endothelin-a receptor antagonist on survival and cardiac function. Circulation 1999;99: 2171–2176.

    Google Scholar 

  35. Chen H, Chau W, Schirger S, Jougaskai M, Leskinen H, Burnett J. Myocardial and circulating endothelin is activated prior to the renin-angiotensin-aldosterone system during the transition to overt congestive heart failure. Sixth International Conference on Endothelin, Montreal, Canada. 1999.

  36. Ohnishi M, Wada A, Tsutamoto T, Fukai D, Kinoshita M. Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. Cardiovasc Res 1998; 39:617–624.

    Google Scholar 

  37. Wada A, Tsutamoto T, Ohnishi M, Sawaki M, Fukai D, Maeda Y, Kinoshita M. Effects of a specific endothelin converting enzyme inhibitor on cardiac, renal and neurohumoral functions in congestive heart failure. Comparison of effects with those of endothelin A receptor antagonists. Circulation 1999; 99:570–577.

    Google Scholar 

  38. CONSENSUS. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian enalapril Survival Study (CONSENSUS). New Eng J Med 1987;316: 1429–1435.

    Google Scholar 

  39. SOLVD. Effect of enalapril on survival of patients with reduced left ventricle ejection fractions and congestive heart failure. New Eng J Med 1991; 325:293–302.

    Google Scholar 

  40. Bayliss J, Norell M, Canepa-Anson R, Poole-Wilson P, Sutton G. Renal vascular response to neuroendocrine vasodilatation in chronic heart failure. Br Heart J 1984;53:107.

    Google Scholar 

  41. Kiwoski W, Sutsch G, Hunziker P, Muller P, Kim J. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732–736.

    Google Scholar 

  42. Love M, Haynes W, Gray G, Webb D, McMurray J. Vasodilator effects of endothelin converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131–2137.

    Google Scholar 

  43. Douglas S. Clinical development of endothelin receptor antagonists (meeting report). Trends in Pharm Sci 1997;18:408–412.

    Google Scholar 

  44. Cannan CR, Burnett JC, Lermaw A. Enhanced coronary vaso constriction to endothelin-B receptor activation in experimental congestive heart failure. Circulation 1996;93:646–651.

    Google Scholar 

  45. Love M, Ferro C, Haynes W, Webb D, McMurray J. Selective or nonselective endothelin receptor blockade in chronic heart failure. Circulation 1996;94:2899–2900.

    Google Scholar 

  46. Spieker LE, Mitrovic V, Noll G, Pacher R, Schulze MR, Muntwyler J, Schalcher C, Kiowski W, Lurcher T. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. J Am Coll Cardiol 2000; 35:1745–1752.

    Google Scholar 

  47. Luscher TF, Barton M. Endothelins and endothelin receptors antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434–2440, 2000.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nambi, P., Clozel, M. & Feuerstein, G. Endothelin and Heart Failure. Heart Fail Rev 6, 335–340 (2001). https://doi.org/10.1023/A:1011464510857

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011464510857

Navigation